Progress in acetylcholinesterase inhibitors for Alzheimer's disease: an update

Bibliography

• Mount C, Downton C. Alzheimer disease: progress or profit? Nat Med 2006;12(7):780-4
   PubMed Web of Science ®Google Scholar
• Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007;6(5):341-2
   PubMed Web of Science ®Google Scholar
• Cummings JL. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. Rev Neurol Dis 2007;4(2):57-62
   PubMedGoogle Scholar
• Swerdlow RH. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? Neurobiol Aging 2007;28(10):1465-80
   PubMedGoogle Scholar
• Bailey P. Biological markers in Alzheimer's disease. Can J Neurol Sci 2007;34(Suppl 1):S72-6
   PubMed Web of Science ®Google Scholar
• Sivaprakasam K. Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation. Curr Med Chem 2006;13(18):2179-88
   PubMed Web of Science ®Google Scholar
• Eckman CB, Eckman EA. An update on the amyloid hypothesis. Neurol Clin 2007;25(3):669-82, vi
   PubMedGoogle Scholar
• Sorrentino G, Bonavita V. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies. Neurol Sci 2007;28(2):63-71
   PubMed Web of Science ®Google Scholar
• Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007;69(16):1622-34
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Alvarez A, Dinamarca MC, et al. Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway. Curr Alzheimer Res 2005;2(3):301-6
   PubMedGoogle Scholar
• Bartolini M, Bertucci C, Bolognesi ML, et al. Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chem Biochem 2007;8(17):2152-61
   Google Scholar
• Zhu X, Lee HG, Perry G, et al. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 2007;1772(4):494-502
   PubMed Web of Science ®Google Scholar
• Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006;6(5):404-16
   PubMed Web of Science ®Google Scholar
• Klafki HW, Staufenbiel M, Kornhuber J, et al. Therapeutic approaches to Alzheimer's disease. Brain 2006;129(11):2840-55
   PubMed Web of Science ®Google Scholar
• Schmitt B, Bernhardt T, Moeller HJ, et al. Combination therapy in Alzheimer's disease: a review of current evidence. CNS Drugs 2004;18(13):827-44
   PubMed Web of Science ®Google Scholar
• Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51(3):347-72
   PubMed Web of Science ®Google Scholar
• Van Der Schyf CJ, Geldenhuys WJ, Youdim MB. Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J Neurochem 2006;99(4):1033-48
   PubMed Web of Science ®Google Scholar
• Relkin NR. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease. Expert Rev Neurother 2007;7(6):735-48
   PubMedGoogle Scholar
• Holzgrabe U, Kapkova P, Alptuzun V, et al. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets 2007;11(2):161-79
   PubMed Web of Science ®Google Scholar
• Martinez A, Castro A. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin Investig Drugs 2006;15(1):1-12
   PubMed Web of Science ®Google Scholar
• Viegas C Jr, Bolzani VS, Barreiro EJ, et al. New anti-Alzheimer drugs from biodiversity: the role of the natural acetylcholinesterase inhibitors. Mini Rev Med Chem 2005;5(10):915-26
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Kumar V, Mal M, et al. Acetylcholinesterase inhibitors from plants. Phytomedicine 2007;14(4):289-300
   PubMed Web of Science ®Google Scholar
• Doraiswamy PM, Xiong GL. Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother 2006;7(1):1-10
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Minarini A, Tumiatti V, et al. Progress in acetylcholinesterase inhibitors for Alzheimer's disease. Expert Opin Ther Patents 2006;16(6):811-23
   Web of Science ®Google Scholar
• Recanatini M, Cavalli A. Actylcholinesterase inhibitors in the context of therapeutic strategies to combat Alzheimer's disease. Expert Opin Ther Patents 2002;12(12):1853-65
   Web of Science ®Google Scholar
• Dorronsoro I, Castro A, Martinez A. Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease-modifying agents. Expert Opin Ther Patents 2003;13(11):1725-32
   Web of Science ®Google Scholar
• Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20(2 Suppl 1):S12-8
   PubMed Web of Science ®Google Scholar
• Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 2006;149(8):998-1012
   PubMed Web of Science ®Google Scholar
• Meunier J, Ieni J, Maurice T. Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther 2006;317(3):1307-19
   PubMed Web of Science ®Google Scholar
• Kadir A, Darreh-Shori T, Almkvist O, et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 2007;In press
   PubMedGoogle Scholar
• Villarroya M, Garcia AG, Marco-Contelles J, et al. An update on the pharmacology of galantamine. Expert Opin Investig Drugs 2007;16(12):1987-98
   PubMed Web of Science ®Google Scholar
• Zhejiang University. Preparation of galathamine derivatives for treatment of senile dementia. CN1847246; 2006
   Google Scholar
• Zhejiang University. Preparation of phenoxyindanone derivatives for treatment of presenile dementia. CN1680279; 2005
   Google Scholar
• Zhejiang University. Preparation of flavonoid derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease. CN1861590; 2006
   Google Scholar
• Ballard CG, Greig NH, Guillozet-Bongaarts AL, et al. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2005;2(3):307-18
   PubMedGoogle Scholar
• Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005;102(47):17213-8
   PubMed Web of Science ®Google Scholar
• Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004;50(4):433-40
   PubMed Web of Science ®Google Scholar
• Neuropharma SA. Butyrylcholinesterase selective inhibitors. WO2005118570; 2005
   Google Scholar
• Shanghai Institute of Materia Medica. Preparation of piperidine derivatives for treating Alzheimer's disease, and improved process for its intermediate 1-benzylpiperidin-4-ylacetonitrile. CN1709873; 2005
   Google Scholar
• Insa Rouen, Gouns, Inc. New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-Alzheimer agents. WO2006103120; 2006
   Google Scholar
• Council of Scientific and Industrial Research. Substituted acid quinolin-9-yl esters useful as acetylcholinesterase inhibitors. WO2006070394; 2006
   Google Scholar
• University of Dortmund, Bern, Max-Planck Gesell. Decaline-derivatives compounds as pharmaceutically active agents. WO2006069787; 2006
   Google Scholar
• Houghton PJ, Ren Y, Howes MJ. Acetylcholinesterase inhibitors from plants and fungi. Nat Prod Rep 2006;23(2):181-99
   PubMed Web of Science ®Google Scholar
• Government of the USA, National Institutes of Health. Tricyclic compounds, preparation thereof and the use thereof as cholinesterase activity inhibitors. WO2006060082; 2006
   Google Scholar
• Liston DR, Nielsen JA, Villalobos A, et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur J Pharmacol 2004;486(1):9-17
   PubMed Web of Science ®Google Scholar
• Diamant S, Podoly E, Friedler A, et al. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2006;103(23):8628-33
   PubMed Web of Science ®Google Scholar
• Council of Scientific and Industrial Research. A pharmaceutical composition useful as acetyl cholinesterase inhibitors. WO2007107846; 2007
   Google Scholar
• Inte:Ligand and Leopold-Franzens University Innsbruck: Use of coumarin derivatives. WO2005102316; 2005
   Google Scholar
• China Pharmaceutical University. Application of sinapine in preventing and treating Alzheimer's disease. CN1615829; 2005
   Google Scholar
• University of Rio De Janeiro, University Estadual Paulista-Unesp. Preparation of piperidine alkaloids for use in pharmaceutical compositions as acetylcholinesterase inhibitors. WO2006039767; 2006
   Google Scholar
• Zhejiang Hisun Pharmaceutical Co., Ltd. Method for preparation of jujubogenin derivatives as acetylcholinesterase inhibitor and antitumor agent. CN1597676; 2005
   Google Scholar
• Leopold-Franzens University Innbruck. Use of extracts and constituents of leontopodium as enhancer of cholinergic function. WO2007006492; 2007
   Google Scholar
• Centre National De La Ricerche Scientifique (CNRS). Tetracyclic terpene series compounds, methods for preparing same, uses thereof as medicines and pharmaceutical compounds containing same. WO2006082126; 2006
   Google Scholar
• Unigen, Inc. Inhibitor for acetylcholinesterase containing gamma-viniferin, vitisin A or extract of grapevine. WO2006025708; 2006
   Google Scholar
• Verkhratsky A, Toescu EC. Endoplasmic reticulum Ca(2+) homeostasis and neuronal death. J Cell Mol Med 2003;7(4):351-61
   PubMed Web of Science ®Google Scholar
• Bojarski L, Herms J, Kuznicki J. Calcium dysregulation in Alzheimer's disease. Neurochem Int 2008;52(4-5):621-33
   PubMed Web of Science ®Google Scholar
• Neuropharma SAU. Marine compounds with calcium channel blocking properties for the treatment of cognitive or neurodegenerative diseases. WO2005123073; 2005
   Google Scholar
• Sun Yat-Sen University. Preparation of 1-azabenzanthrone derivatives as acetylcholinesterase inhibitors. CN101020659; 2007
   Google Scholar
• Li W, Hao JL, Tang Y, et al. Structural comparisons of meptazinol with opioid analgesics. Acta Pharmacol Sin 2005;26(3):334-8
   PubMed Web of Science ®Google Scholar
• Fudan University. Manufacture of meptazinol and its salt with optical purity used as analgesics or anti-Alzheimer agents. CN1850804; 2006
   Google Scholar
• Ling KH, Liou HH, Yang CM, et al. Isolation, chemical structure, acute toxicity, and some physicochemical properties of territrem C from Aspergillus terreus. Appl Environ Microbiol 1984;47(1):98-100
   PubMed Web of Science ®Google Scholar
• Ling KH, Yang CK, Peng FT. Territrems, tremorgenic mycotoxins of Aspergillus terreus. Appl Environ Microbiol 1979;37(3):355-7
   PubMed Web of Science ®Google Scholar
• Zhejiang Hisun Group. Preparation of 2H-pyran-2-one derivatives as acetylcholinesterase inhibitors for treatament of Alzheimer's disease and tumor. CN1721416; 2006
   Google Scholar
• Myriad Genetics. Pharmaceutical methods, dosing regimes and dosage for the treatment of Alzheimer's disease. WO2005065069; 2005
   Google Scholar
• Myriad Genetics. Pharmaceutical compostions containing acetylcholine esterase inhibitors for treating neurodegenerative disorders. WO2006020853; 2006
   Google Scholar
• Myriad Genetics. Pharmaceutical compositions and method for treating neurodegenerative disorders. WO2006020850; 2006
   Google Scholar
• Myriad Genetics. Pharmaceutical composition and method for treating neurodegenerative disorders. WO2006020852; 2006
   Google Scholar
• Mayo Foundation for Medical Education and Research. Method of reducing abeta42 and treating diseases. US20060004086; 2006
   Google Scholar
• Dainippon Sumitomo Pharma Co., Ltd. Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 2-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivative. WO099696; 2005
   Google Scholar
• Gottesmann C. GABA mechanisms and sleep. Neuroscience 2002;111(2):231-9
   PubMed Web of Science ®Google Scholar
• Chebib M, Vandenberg RJ, Froestl W, et al. Unsaturated phosphinic analogues of gamma-aminobutyric acid as GABA(C) receptor antagonists. Eur J Pharmacol 1997;329(2-3):223-9
   PubMedGoogle Scholar
• Froestl W, Mickel SJ, Von Sprecher G, et al. Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. J Med Chem 1995;38(17):3313-31
   PubMed Web of Science ®Google Scholar
• Johns Hopkins University. Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor. WO2005112946 (2005)
   Google Scholar
• Shimada F, Shiga Y, Morikawa M, et al. The neuroprotective agent MS-153 stimulates glutamate uptake. Eur J Pharmacol 1999;386(2-3):263-70
   PubMed Web of Science ®Google Scholar
• Johns Hopkins University. Prevention and treatment of cognitive impairment. US0014801; 2006
   Google Scholar
• Schering Co. Macrocyclic beta-secretase inhibitors. WO2006014944; 2006
   Google Scholar
• Schering Co. Substituted amide beta secretase inhibitors. WO2006014762; 2006
   Google Scholar
• Mcshea A, Lee HG, Petersen RB, et al. Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta 2007;1772(4):467-72
   PubMed Web of Science ®Google Scholar
• Gregory CW, Atwood CS, Smith MA, et al. Antigonadotropins: a novel strategy to halt Alzheimer's disease progression. Curr Pharm Des 2006;12(6):685-90
   PubMedGoogle Scholar
• Voyager Pharmaceutical Co. Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of Alzheimer's disease. WO2006071274; 2006
   Google Scholar
• Rabinoff. Novel medication treatment and delivery strategies for Alzheimer's disease and other disorders with memory impairment, and possible treatment strategies for memory improvement. US20060194723; 2006
   Google Scholar
• Epix Pharmaceuticals, Inc. Compositions and methods for treating CNS disorders. WO2007058805; 2007
   Google Scholar
• Wyeth. Method for the treatment of cognitive dysfunction. WO2007087151; 2007
   Google Scholar
• University Of Barcelona. Acetylcholineserase-inhibiting compounds for treating Alzheimer's disease. WO2007122274; 2007
   Google Scholar
• Neuropharma SA. Dual binding site acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. WO032929; 2004
   Google Scholar
• Youdim MB, Amit T, Bar-Am O, et al. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs: ladostigil. Neurotox Res 2006;10(3-4):181-92
   PubMed Web of Science ®Google Scholar
• Teva Pharmaceutical Industries Ltd. Propargylated aminoindans, processes for preparation, and use thereof. WO2007100583; 2007
   Google Scholar
• Ferrer Int. Preparation of 5-amino-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid derivatives. ES2277741; 2007
   Google Scholar
• Holmquist L, Stuchbury G, Berbaum K, et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007;113(1):154-64
   PubMed Web of Science ®Google Scholar
• Rosini M, Andrisano V, Bartolini M, et al. Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem 2005;48(2):360-3
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Minarini A, Tumiatti V, et al. Lipoic acid, a lead structure for multi-target-directed drugs for neurodegeneration. Mini Rev Med Chem 2006;6(11):1269-74
   PubMed Web of Science ®Google Scholar
• Alma Mater Studiorum–Università Di Bologna. Organic compounds useful for the treatment of Alzheimer's disease. WO2006080043 (2006)
   Google Scholar
• Bolognesi ML, Banzi R, Bartolini M, et al. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J Med Chem 2007;50(20):4882-97
   PubMed Web of Science ®Google Scholar
• Alma Mater Studiorum–Università Di Bologna. Synthesis of organic compounds. WO2006134457; 2006
   Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 2001;46(1-3):3-26
   PubMed Web of Science ®Google Scholar
• Muller-Kuhrt L. Putting nature back into drug discovery. Nat Biotechnol 2003;21(6):602
   PubMed Web of Science ®Google Scholar
• Butler MS, Newman DJ. Mother Nature's gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery. Prog Drug Res 2008;65(1):3-44
   Google Scholar
• Ma X, Tan C, Zhu D, et al. Huperzine A from Huperzia species: an ethnopharmacolgical review. J Ethnopharmacol 2007;113(1):15-34
   PubMed Web of Science ®Google Scholar
• Zhang HY, Tang XC. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 2006;27(12):619-25
   PubMed Web of Science ®Google Scholar
• Izzo AA, Capasso F. Herbal medicines to treat Alzheimer's disease. Trends Pharmacol Sci 2007;28(2):47-8
   PubMed Web of Science ®Google Scholar
• Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J Food Sci 2008;73(1):R14-9
   PubMed Web of Science ®Google Scholar
• Zhang HY. One-compound-multiple-targets strategy to combat Alzheimer's disease. FEBS Lett 2005;579(24):5260-4
   PubMed Web of Science ®Google Scholar